CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
EAA171 ECOG-ACRIN Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM) Adult CIRB - Late Phase Emphasis
EAA172 ECOG-ACRIN Phase 1/2 Study of Daratumumab, Bortezomib, Dexamethasone with or without Venetoclax in Relapsed/Refractory Multiple Myeloma with Assessment for t(11;14) Status Adult CIRB - Late Phase Emphasis
EAA173 ECOG-ACRIN Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Adult CIRB - Late Phase Emphasis
EAA181 ECOG-ACRIN Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation Adult CIRB - Late Phase Emphasis
EAA232 ECOG-ACRIN A Randomized Phase II Trial for High-Risk Multiple Myeloma that is Refractory or in First Relapse with Daratumumab, Teclistamab (DT) versus Daratumumab, Pomalidomide, dexamethasone (DPd) or Daratumumab, Carfilzomib, dexamethasone (DKd) Adult CIRB - Late Phase Emphasis
EAA241 ECOG-ACRIN A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) Adult CIRB - Late Phase Emphasis
EAA242 ECOG-ACRIN Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma Adult CIRB - Early Phase Emphasis
EAE161 ECOG-ACRIN Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma Adult CIRB - Late Phase Emphasis
EAF151 ECOG-ACRIN Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma Adult CIRB - Late Phase Emphasis
EAF223 ECOG-ACRIN Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE) Adult CIRB - Late Phase Emphasis